New Oral Drug Saroglitazar Triples Liver Response Rates in Hard-to-Treat Bile Duct Disease
A phase III trial shows saroglitazar helped 57% of primary biliary cholangitis patients achieve biochemical response vs just 10% on placebo.
Summary
Primary biliary cholangitis (PBC) is a chronic liver disease where bile ducts progressively deteriorate, leading to inflammation, fibrosis, and cirrhosis. About 40% of patients don't respond adequately to the standard first-line drug. A new oral therapy called saroglitazar, tested in a randomized phase III trial of 148 patients, achieved biochemical response in nearly 57% of treated patients at one year, compared to under 10% on placebo. The drug works by activating dual PPAR receptors, which help regulate liver inflammation and bile metabolism. The FDA has granted it Priority Review status, with a decision expected by late 2026. This represents a meaningful advance for a disease that disproportionately affects women and currently has limited treatment options beyond the first-line therapy.
Detailed Summary
Primary biliary cholangitis (PBC) is a chronic, progressive liver disease in which the immune system attacks and destroys bile ducts, causing bile to accumulate and trigger inflammation, scarring, and ultimately cirrhosis. It predominantly affects women — roughly 65 per 100,000 in the U.S. — and while ursodeoxycholic acid (UDCA) is the established first-line treatment, around 40% of patients fail to respond adequately and 5–10% cannot tolerate it at all. For these patients, options have been limited.
The EPICS-III randomized clinical trial, presented at the European Association for the Study of the Liver (EASL) annual meeting, tested saroglitazar magnesium — a novel dual PPAR alpha/gamma agonist taken as a once-daily 1-mg oral tablet — against placebo in 148 adults who had inadequate responses or intolerance to UDCA. The primary endpoint was biochemical response at 52 weeks, defined by specific reductions in alkaline phosphatase (ALP) and normal bilirubin levels.
Results were striking: 56.7% of saroglitazar-treated patients achieved biochemical response at one year versus only 9.8% on placebo — a highly statistically significant difference. In the subgroup with lower baseline ALP (no more than three times the upper limit of normal), response rates climbed to 83.1% with saroglitazar versus 14.7% with placebo, though this subgroup analysis did not reach statistical significance independently.
Saroglitazar's safety profile was reported as favorable, and its mechanism — dual PPAR activation — targets liver metabolism at a fundamental level, potentially addressing inflammation and fibrosis pathways relevant beyond PBC, including dyslipidemia in type 2 diabetes. The FDA has granted Priority Review designation with a decision expected by November 27, 2026.
Important caveats apply: the trial was relatively small at 148 patients, conducted across four countries with varying baseline characteristics, and longer-term outcomes including cirrhosis prevention and survival data are not yet available. Biochemical response is a surrogate marker, not a direct measure of clinical outcomes like liver failure prevention.
Key Findings
- Saroglitazar achieved 56.7% biochemical response at 1 year vs 9.8% placebo in PBC patients unresponsive to standard therapy.
- Patients with lower baseline liver enzyme levels responded even better, reaching 83.1% response rate with saroglitazar.
- The drug is a once-daily oral 1-mg tablet with a reported favorable safety profile in the trial.
- FDA has granted Priority Review; approval decision expected by November 27, 2026.
- Saroglitazar is also being evaluated for dyslipidemia in type 2 diabetes, broadening its potential longevity relevance.
Methodology
This is a meeting coverage news report from MedPage Today summarizing data presented at EASL 2026 from the EPICS-III phase III randomized controlled trial. The RCT design with placebo control and a statistically significant primary endpoint provides credible evidence, though full peer-reviewed publication is not yet cited.
Study Limitations
The trial enrolled only 148 participants across four countries, limiting generalizability. Biochemical response is a surrogate endpoint — long-term outcomes like cirrhosis prevention, transplant rates, and mortality were not reported. Full peer-reviewed publication has not yet been cited, so complete safety and subgroup data require verification.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.